<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03459144</url>
  </required_header>
  <id_info>
    <org_study_id>2017KYPJ093</org_study_id>
    <nct_id>NCT03459144</nct_id>
  </id_info>
  <brief_title>Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen</brief_title>
  <official_title>Comparison of the Effects of Photodynamic Therapy, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the outcomes of different treatment methods including
      photodynamic therapy (PDT), intravitreal ranibizumab injection (IVR) and combination therapy
      under the &quot;1+PRN&quot; treatment regimen for polypoidal choroidal vasculopathy (PCV) and find the
      optimal treatment for PCV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The optimal treatment for PCV is still under debate. Little knowledge is known about the
      treatment effect of &quot;1+pro re nata(PRN)&quot; treatment regimen for PCV. The aim of this study is
      to compare the outcomes of different treatment methods including PDT, IVR and combination
      therapy under the &quot;1+PRN&quot; treatment regimen for PCV.

      The study is the first prospective randomized controlled trial about different treatment
      methods on PCV under &quot;1+PRN&quot; treatment regimen. The null hypothesis of the study is that
      combination therapy may be the optimal treatment method for PCV. The primary outcome measures
      is the Best-corrected visual acuity (BCVA) of the participants at 1 year after treatment.
      Besides, the slit-lamp examination, tonometry, funduscopy, and OCT, FFA, ICGA examinations
      will also be compared between different groups to find the optimal treatment for PCV.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2012</start_date>
  <completion_date type="Actual">July 30, 2015</completion_date>
  <primary_completion_date type="Actual">July 30, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>12 months</time_frame>
    <description>the best corrected visual acuity is the Primary Outcome Measure</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Polypoidal Choroidal Vasculopathy</condition>
  <arm_group>
    <arm_group_label>photodynamic therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given the standard verteporfin photodynamic therapy at baseline followed by additional standard verteporfin PDT as needed (every three months)(namely 1+PRN regimen).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intravitreal ranibizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the intravitreal ranibizumab treatment (0.05mg) at baseline and additional intravitreal ranibizumab will be given to the participants when necessary (every month) (namely 1+PRN regimen).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>combination therapy of PDT and IVR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given the standard verteporfin photodynamic therapy followed by intravitreal ranibizumab (0.05mg) 72h after the standard verteporfin PDT treatment at baseline. Additional verteporfin photodynamic therapy and intravitreal ranibizumab (0.05mg) will be given to the participants when necessary (every month)(namely 1+PRN regimen).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>verteporfin</intervention_name>
    <description>Participants will receive the intravitreal ranibizumab treatment (0.05mg) at baseline and additional intravitreal ranibizumab(0.05mg) will be given to the participants when necessary（every three months）.</description>
    <arm_group_label>photodynamic therapy</arm_group_label>
    <arm_group_label>intravitreal ranibizumab</arm_group_label>
    <arm_group_label>combination therapy of PDT and IVR</arm_group_label>
    <other_name>ranibizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>verteporfin and ranibizumab</intervention_name>
    <description>Participants will be given the standard verteporfin photodynamic therapy followed by intravitreal ranibizumab (0.05mg) 72h after the PDT treatment at baseline. Additional verteporfin photodynamic therapy and intravitreal ranibizumab (0.05mg) will be given to the participants when necessary.</description>
    <arm_group_label>photodynamic therapy</arm_group_label>
    <arm_group_label>intravitreal ranibizumab</arm_group_label>
    <arm_group_label>combination therapy of PDT and IVR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. active macula-involved polypoidal lesions evidenced by ICGA;

          2. greatest linear dimension of 5400 μm or less assessed by ICGA;

          3. follow-up of at least 12 months.

        Exclusion Criteria:

          1. any other ocular disease, such as ocular trauma, glaucoma, uveitis, diabetic
             retinopathy, angioid streaks, pathologic myopia, or presumed ocular histoplasmosis
             syndrome;

          2. any systemic contraindication to the PDT, IVR, sodium fluorescein, or indocyanine
             green dyes;

          3. any severe uncontrolled systemic disease, such as uncontrolled hypertention, coronary
             heart disease, liver failure, or kidney failure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chenjin Jin, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2018</study_first_submitted>
  <study_first_submitted_qc>March 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2018</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Jin Chen-jin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>polypoidal choroidal vasculopathy</keyword>
  <keyword>photodynamic therapy</keyword>
  <keyword>ranibizumab</keyword>
  <keyword>combination therapy</keyword>
  <keyword>cost-benefit</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Verteporfin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

